INTRODUCTION
Receptor-activated Ca# + channels are essential to the actions of hormones and growth factors on non-excitable and some excitable cells [1] . On the basis of cation specificity and the likely mechanism of activation, three groups of receptor-activated Ca# + channels have been identified : ligand-gated channels, intracellular messenger-activated channels and store-activated channels [2] . The last-mentioned process, initially described by Putney [3] , involves the release of Ca# + from a component of the smooth endoplasmic reticulum (SER), which in turn leads to activation of Ca# + inflow across the plasma membrane. This form of receptor-activated Ca# + channel is prevalent in many types of animal cell and is important in increases in intracellular Ca# + concentration promoted by extracellular signals [4] .
Neither the structures nor the mechanisms of activation of store-activated calcium channels (SACCs) are well understood [4] . Three mechanisms have emerged to explain how the release of Ca# + from a region of the SER leads to activation of the plasma membrane SACCs. These are : (1) conformational coupling between one or more proteins in the SER and the SACCs [5] , (2) the formation and action of a mobile intracellular messenger [6] [7] [8] , and (3) the transport of vesicles containing SACCs from an intracellular site to the plasma membrane where the SACCs are inserted into the plasma membrane by fusion of the vesicle and plasma membranes [2, 9] (compare the insertion of glucose . It is concluded that membrane fusion processes are unlikely to be involved in the link between the release of Ca# + from the endoplasmic reticulum and activation of SACCs. The idea that this link is achieved by direct interaction of a protein(s) in the endoplasmic reticulum membrane with the SACC protein is briefly discussed.
transporters in the plasma membrane [10] ). Evidence for the vesicle-mediated insertion hypothesis comes directly from experiments with primaquine and chloroquine, which inhibit storeactivated Ca# + inflow in megakaryocytes [9] , and indirectly from the observations that the activation of SACCs requires a monomeric and\or trimeric GTP-binding regulatory protein (Gprotein) [11] [12] [13] [14] . Primaquine and chloroquine inhibit vesicle budding and fusion in a number of intracellular pathways such as protein secretion and recycling of plasma membrane receptors [15, 16] , but also inhibit the activities of several membraneassociated enzymes [17] [18] [19] , as well as affecting membrane properties [20] . G-proteins are known to be required for membrane fusion events [21, 22] .
In the present experiments we have tested the vesicle-mediated insertion hypothesis for the activation of SACCs in Xenopus lae is oocytes by using primaquine, agents that inhibit or activate G-protein function, and reagents that disrupt the cytoskeleton because normal integrity of the cytoskeleton is required for vesicle trafficking [23] . X. lae is oocytes possess well-characterized store-activated Ca# + channel(s) [24, 25] and their large size allows the ready introduction of reagents to the cytoplasmic space. It was found that primaquine inhibits store-activated Ca# + inflow in Xenopus oocytes. However, this inhibition is due to a direct interaction of primaquine with SACCs and not to an inhibition of membrane fusion. Moreover, reagents that disrupt the functions of G-proteins or the cytoskeleton did not inhibit the activation of SACCs so that it is concluded that membrane fusion is not required for the activation of SACCs in Xenopus oocytes.
MATERIALS AND METHODS

Materials
Primaquine, chloroquine, Brefeldin A, pertussis toxin, cytochalasin B, colchicine and staurosporine were from SigmaAldrich (Castle Hill, N.S.W., Australia) ; cholera toxin was from Sapphire Bioscience (Alexandria, N.S.W., Australia) ; and desferrioxamine mesylate (deferoxamine) was from Ciba-Geigy Australia (Lane Cove, N.S.W., Australia). Lovastatin was a gift from Merck, Sharp and Dohme. The synthesis of Drosophila trpl cRNA and expression in Xenopus oocytes were performed as described previously [26] . All other reagents and X. lae is were obtained from the sources described previously [14, 26] . Peptide Arf-1 (2-17) was synthesized by Dr. B. Kemp (St. Vincent's Institute of Medical Research, Melbourne, Victoria, Australia).
Methods
The isolation of oocytes (stages V and VI) from wild-type and albino X. lae is and the incubation of oocytes were performed as described previously [26, 27] . Microinjection of agents into oocytes, measurement of the fluorescence of oocytes loaded with fluo-3, determination of initial rates of increase in Ca# ) were performed as described previously [26, 27] . A period of 20 min was allowed for recovery of the oocytes after microinjection. 
Analysis of results
Except where indicated otherwise, the results are the means pS. E. M. for the number of oocytes indicated in parenthesis.
RESULTS
Effects of primaquine
The addition of extracellular Ca# + (Ca# The effects of primaquine on the Ins(1,4,5)P $ F-stimulated Ca# + ! -induced increase in fluorescence were compared with those of Gd$ + , a potent inhibitor of SACCs [27, 29] . As expected, Gd$ + oocytes]q and microinjection of Drosophila trpl cRNA were performed as described in the Materials and methods section. Primaquine was added before the microinjection of fluo-3. The results are the meanspS.E.M. for the number of oocytes shown in parenthesis. Degrees of significance, determined with Student's t test, for unpaired samples were : P 0.001 for cholera toxin compared with control ; P 0.3 for cholera toxin plus primaquine compared with control plus primaquine ; P 0.01 for trpl cRNA-injected compared with ' mock '-injected ; P 0.05 for trpl cRNA-injected plus primaquine compared with ' mock '-injected plus primaquine.
Primaquine
Initial stimulated Ca# + o -induced increase in fluo-3 fluorescence by 30 % (n l 8) (results not shown).
To assess whether inhibition of the Ins(1,4,5)P $ F-stimulated increase in Ca# + o -induced fluo-3 fluorescence by primaquine was reversible, oocytes were incubated for 2.5 h in the presence of 1 mM primaquine before the microinjection of Ins(1,4,5)P $ F and fluo-3. Half of the oocytes were then maintained in primaquinefree media and the other half were incubated in the presence of 1 mM primaquine. The rates of increase in Ca# + o -induced fluorescence were 0.61p0.08 (n l 10) for oocytes exposed to primaquine for the full incubation period, 2.14p0.28 (n l 9) for oocytes incubated with primaquine in the initial phase, and 3.65p0.23 (n l 12) (all in fluorescence units\min) for oocytes not exposed to primaquine at any time. Thus a considerable proportion of the effect of primaquine could be reversed. Albino oocytes were microinjected with ' caged ' Ins(1,4,5)P 3 , and fluo-3 and fluorescence measurements performed on individual oocytes with a fluorescence microscope, as described in the Materials and methods section. Breaks in the traces correspond to short intervals when light incident on the photomultiplier was blocked in order to photolyse ' caged ' Ins(1,4,5)P 3 (indicated by the arrows). Upper panel : oocytes were initially present in Ca 2 + -free medium. CaCl 2 (6.6 mM) was added at 10.5 min and primaquine (1 mM) at 22 min, as indicated by the horizontal bars. Lower panel : oocytes, initially present in Ca 2 + -free medium, were exposed to primaquine (1 mM) 6 min before the first photolysis event. Calcium (6.6 mM) was added as indicated by the horizontal bar. In both panels the traces shown were obtained with a single oocyte and are representative of the results obtained for three oocytes.
height of the fluorescence peak (mV). The values for this ratio were 1.31p0.10 (n l 16), 1.30p0.08 (n l 7) and 1.14p0.14 (n l 3) for oocytes incubated in the absence of primaquine and in the presence of 0.5 and 1.0 mM primaquine respectively. Photolysis of ' caged ' Ins(1,4,5)P $ in control oocytes incubated in the presence of Ca# + o (6.6 mM) caused a more prolonged increase in fluorescence (Figure 2 , upper panel, curve 3 ; compare curves 1 and 2) owing to the stimulation by Ins(1,4,5)P $ of Ca# + inflow as well as Ca# + release from the SER. The ratio of peak area to peak height was 5.28p0.65 (n l 12) which is 4-fold higher than the value obtained in the absence of added Ca# area to peak height was 2.74p0.38 (n l 9) in the presence of 6.6 mM Ca# + o and 1 mM primaquine. By Student's t test for unpaired samples, P 0.001 for the ratio in the presence of 6.6 mM Ca# + and 1 mM primaquine compared with the ratio in the presence of 6.6 mM Ca# + .
The results above indicate that primaquine inhibits Ca# + inflow when added either before activation of the SACCs [2.5 or 5.5 h before injection of Ins(1,4,5)P $ F] or when the SACCs are already activated [addition of primaquine 30 min after Ins(1,4,5)P $ F injection]. Thus the effect of primaquine might be either on the process that activates the SACCs or on the movement of Ca# + through the SACCs. To investigate the second possibility further, the effects of primaquine added when the Ca# + o -induced increase in fluorescence had reached a plateau were compared with those of Gd$ + . The addition of either primaquine or Gd$ + caused a decrease in fluorescence that, after approx. 20 min, approached a steady-state value approx. 10 % greater than the initial (zero time) value (Figure 3) . The time course for the effect of primaquine was identical with that for Gd$ + (Figure 3) .
The effects of primaquine on two other divalent cation channels, the cholera toxin-activated divalent cation channel previously identified in Xenopus oocytes [30] and the Drosophila Trpl-, Ca# + -and Ins(1,4,5)P $ -activated non-selective cation channel [31] expressed in Xenopus oocytes [26] , were investigated. Primaquine inhibited cholera toxin-stimulated Ca# + inflow (Table  1) . In oocytes expressing the Trpl protein, the rate of the Ins(1,4,5)P $ F-stimulated increase in Ca# + o -induced fluo-3 fluorescence was 44 % higher than that in ' mock '-injected oocytes (Table 1) . Primaquine inhibited the rate of the Ins(1,4,5)P $ Fstimulated increase in Ca# + o -induced fluo-3 fluorescence in both ' mock '-and Trpl cRNA-injected oocytes ( Table 1) . (Figure 4 and Table 2 ), as shown previously [32] . At 150 µM GTP[S] the degree of inhibition was 85 % (results not shown). p[NH]ppG, NaF, and AlCl $ plus NaF (AlF % − ), but not guanosine 5h-[β-thio]diphosphate (GDP[S]) or GTP, also inhibited the Ins(1,4,5)P $ F-stimulated increase in fluo-3 fluorescence (Table 2) . Deferoxamine, which chelates tervalent cations such as Al$ + [33] , largely prevented the effect of AlCl $ plus NaF ( Table  2) . The inhibition by GTP[S] and AlF % − was not prevented by the co-injection of GTP (Table 2) . However, as shown by Petersen and Berridge [32] , the effect of GTP[S] was largely prevented by staurosporine, an inhibitor of protein kinase C [34] (Table 2 and Figure 4) .
Effects of inhibitors and activators of G-protein function
50-60 %
No detectable inhibition of Ins(1,4,5)P $ F-stimulated Ca# + inflow was observed when oocytes were preincubated for : 27 h with pertussis toxin, which ADP-ribosylates G i , G o and G t (transducin) [35] ; 24 h with lovastatin, which inhibits the isoprenylation of some monomeric G-proteins [36, 37] ; or 5 h with Brefeldin A, an inhibitor of membrane fusion events involving Arf proteins [38] (results not shown). The peptide Arf-1 (2-17), which inhibits the functions of Arf proteins, including the budding of transport vesicles involved in protein trafficking [39] , also had no effect on store-activated Ca# + inflow (results not shown). The nucleotides, NaF, AlCl 3 and NaCl (intracellular concentrations shown) were co-injected into albino Xenopus oocytes with fluo-3 and Ins(1,4,5)P 3 F. Staurosporine and deferoxamine (extracellular concentrations shown) were added to the incubation medium 4 and 2 h respectively before microinjection of Ins(1,4,5)P 3 F and fluo-3, and were also present during the measurement of fluorescence analysis. Initial rates of increase in fluo-3 fluorescence were measured after the addition of 6. 2.23p0.38 (4) NaCl (5 mM) plus AlCl 3 (15 µM) plus deferoxamine (100 µM) 3.99p0.26 (11) NaF (5 mM) plus AlCl 3 (15 µM) plus deferoxamine (100 µM) 3.59p0.37 (9) stimulation of Ca# + inflow [27] and the loss of black pigmentation from the animal hemisphere induced by a high concentration of GTP[S] (0.8 mM) (results not shown), indicating that these agents had disrupted the cytoskeleton.
Effects of cytochalasin B and colchicine
DISCUSSION
Action of primaquine
The results show that primaquine rapidly and reversibly inhibits Ins(1,4,5)P $ F-stimulated Ca# + inflow in Xenopus oocytes without a detectable effect on the release of Ca# + from intracellular stores. This last result indicates that the effects of primaquine are unlikely to be due to the quenching of fluo-3 fluorescence or the chelation of intracellular Ca# + . Two explanations for the primaquine-induced inhibition of Ins(1,4,5)P $ F-stimulated Ca# + inflow (assessed by measurement of the initial rate of Ca# + o -induced increase in fluo-3 fluorescence) are that primaquine either directly inhibits the flow of Ca# + through open SACCs or that it inhibits the process by which Ca# + release from the SER activates SACCs. In relation to the second explanation, it has been proposed that the activation of SACCs by Ca# + release from the SER involves the movement of vesicles that contain SACCs to the plasma membrane and insertion of SACCs into the plasma membrane by fusion of the vesicle and the plasma membranes [2, 9] . Inactivation of SACCs might then involve endocytotic retrieval from the plasma membrane [9] . If this were the mechanism of activation of SACCs, the addition of primaquine before Ins(1,4,5)P $ F might inhibit SACC activation by inhibiting the formation of transport vesicles [40] and hence the insertion of SACCs into the plasma membrane. The addition of primaquine after Ins(1,4,5)P $ F might reverse SACC activation if the endocytosis of SACCs already in the plasma membrane continued in the presence of primaquine.
Several observations indicate that primaquine inhibits Ca# + movement through the SACC pore rather than a step in SACC activation. (1) The action of primaquine was not specific for SACCs. Thus primaquine inhibited basal (no agonist) Ca# + inflow and Ca# + inflow through cholera toxin-activated divalent cation channels and Drosophila Trpl divalent cation channels. These are not SACCs and are not activated by Ca# + release from the SER [30, 31] . (2) The time courses for the decrease in fluorescence caused by the addition of primaquine or Gd$ + , a potent inhibitor of Ca# + movement through SACCs [27, 29] , to Ins(1,4,5)P $ F-loaded oocytes after the Ca# + o -induced increase in fluorescence had reached a plateau were almost identical. In this experiment the decrease in fluorescence after the inhibition of Ca# + inflow is due to continued removal of Ca# + from the cytoplasmic space by the plasma membrane and SER (Ca# + j Mg# + )ATPases [41] . (3) The rate of decrease in fluorescence at room temperature after primaquine addition at the fluorescence plateau [as described in (2)] was faster than predicted if endocytosis (of the Ca# + channel protein) were to determine the net rate of inhibition by primaquine of Ca# + inflow [15, 42] . (4) Although the possibility that primaquine inhibits one or more steps in the pathway of activation of SACCs as well as inhibiting Ca# + flow through the SACC pore cannot be completely eliminated, it is considered unlikely. Moreover the conclusion that primaquine interacts with the SACC protein is consistent with reports that primaquine has a wide range of effects on intracellular processes [16] [17] [18] 20, 42, 43] .
The conclusions just described differ from that reached by Somasundaram et al. [9] in a study of primaquine inhibition of I CRAC (calcium-release-activated current) in rat megakaryocytes. Those authors concluded that the most likely explanation for the effect of primaquine was inhibition of trafficking and recycling of SACCs, although they could not eliminate a direct inhibition by primaquine of the SACCs. The differences in interpretation of the results obtained for megakaryocytes and oocytes might reflect differences in the mechanisms of activation of the SACCs in the two cell types and the fact that primaquine affects several processes in intact cells [16] [17] [18] 20, 42, 43] .
Role of membrane fusion in the activation of SACCs
As part of a test of the vesicle-mediated membrane insertion hypothesis for the activation of SACCs, reagents that interfere with the functions of G-proteins were employed to determine whether a trimeric and\or a monomeric G-protein is required in the link between Ca# + release from the SER to the activation of SACCs because G-proteins are required for membrane fusion events [21, 22] . As shown by others [11] [12] [13] − is that they each activate G q/"" , which couples to phospholipase Cβ, increase the formation of diacylglycerol, and activate protein kinase C, which in turn inhibits a step in the link between the release of Ca# + from SER and the activation of SACCs [32] . Thus it is concluded that neither a trimeric nor a monomeric G-protein is part of the SACC activation pathway in Xenopus oocytes.
This last-mentioned finding provides indirect evidence that SACC activation does not involve vesicle-mediated insertion of SACC proteins into the plasma membrane. More direct evidence for this conclusion comes from the experiments conducted with primaquine and colchicine\cytochalasin B. Thus there is no evidence that the primaquine inhibition of SACC activation is due to inhibition of the budding and fusion of vesicles. Moreover the disruption of microfilaments and microtubules by colchicine\cytochalasin B, which might also be expected to disrupt membrane fusion processes [47] , did not inhibit SACC activation. Thus it is concluded that it is unlikely that SACC activation in Xenopus oocytes involves vesicle-mediated insertion of SACC proteins into the plasma membrane. Two other possible mechanisms for SACC activation are the formation of a mobile intracellular messenger [6] [7] [8] and conformational coupling between one or more proteins in the SER and one or more proteins in the SACC [5] . Xenopus oocytes contain putative anatomical junctions between regions of the SER and the plasma membrane [48] , as required in the conformational coupling model. However, although a mobile intracellular messenger has not been identified [49] , it is currently not possible to exclude either hypothesis. Thus further investigation is required to elucidate the mechanism of activation of SACCs in Xenopus oocytes.
